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Objectives We compared the safety of different devices by screening for subclinical intracranial embolic events after pulmo-
nary vein isolation with either conventional irrigated radiofrequency (RF) or cryoballoon or multielectrode phased
RF pulmonary vein ablation catheter (PVAC).
Background New devices specifically designed to facilitate pulmonary vein isolation procedures have recently been introduced.
Methods This prospective, observational, multicenter study included patients with symptomatic atrial fibrillation referred
for pulmonary vein isolation. Ablation was performed using 1 of the 3 catheters. Strict periprocedural anticoagu-
lation, with intravenous heparin during ablation to achieve an activated clotting time 300 s, was ensured in all
patients. Cerebral magnetic resonance imaging was performed before and after ablation.
Results Seventy-four patients were included in the study: 27 in the irrigated RF group, 23 in the cryoballoon group, and
24 in the PVAC group. Total procedure times were 198  50 min, 174  35 min, and 124  32 min, respec-
tively (p  0.001 for PVAC vs. irrigated RF and cryoballoon). Findings on neurological examination were normal
in all patients before and after ablation. Post-procedure magnetic resonance imaging detected a single new em-
bolic lesion in 2 of 27 patients in the irrigated RF group (7.4%) and in 1 of 23 in the cryoballoon group (4.3%).
However, in the PVAC group 9 of 24 patients (37.5%) demonstrated 2.7  1.3 new lesions each (p  0.003 for
the presence of new embolic events among the 3 groups).
Conclusions The PVAC is associated with a significantly higher incidence of subclinical intracranial embolic events. Further
study of the causes and significance of these emboli is required to determine the safety of the PVAC. (J Am
Coll Cardiol 2011;58:681–8) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.04.010Left atrial catheter ablation is an increasingly recommended
treatment for atrial fibrillation (AF). Although many dif-
ferent techniques have been described, pulmonary vein
isolation (PVI) remains a basic and central endpoint (1,2).
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2011, accepted April 27, 2011.However, PVI performed with conventional radiofrequency
(RF) (externally irrigated RF) ablation catheters remains a
technically demanding technique, with a relatively long
learning curve.
See page 689
To facilitate these procedures, new devices have been
developed to allow faster and easier PVI. Two of these
devices have been approved for routine clinical practice in
Europe: the cryoballoon (3) and the multielectrode duty-
cycled RF ablation catheter (4).
However, published data on these new devices mainly
focus on its efficacy. Safety data are scarce. In particular,
although procedure-related strokes or transient ischemic
attacks occur in approximately 1% of patients undergoing
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cent evidence suggests a higher
rate of subclinical cerebral emboli
detected by imaging (6). We
aimed to compare the safety pro-
file of these devices by assessing
the incidence of new subclinical
embolic lesions by cerebral mag-
netic resonance imaging (MRI)
before and after PVI.
Methods
Patient characteristics. We pro-
spectively included 74 patients
(68% men, age 61  9 years)
with highly symptomatic, drug-
resistant paroxysmal (62%) or
persistent AF referred for cathe-
ter ablation to 3 high-volume
centers participating in the study.
Exclusion criteria were long-
standing persistent AF, the need for further left atrial
ablation other than PVI, and any contraindication to un-
dergoing MRI.
The study protocol was approved by local ethics commit-
tee/boards, and all patients signed an informed consent.
Catheter ablation procedures. All patients underwent
PVI alone with: 1) a conventional externally irrigated RF
catheter; 2) an Arctic Front cryoballoon (Medtronic, Min-
neapolis, Minnesota); or 3) a multielectrode duty-cycled RF
pulmonary vein ablation catheter (PVAC) (Medtronic Ab-
lation Frontiers, Carlsbad, California). All ablations were
performed by operators with sufficient expertise in the
respective techniques. Specifically, RF ablation procedures
were performed in all 3 participating centers, cryoballoon
ablations in Bad Krozingen, Germany, and PVAC proce-
dures in Bordeaux, France, and Köln, Germany. The
procedures were performed with the patients under either
general anesthesia or conscious sedation, according to the
usual practice at each center.
CONVENTIONAL RF PVI. Externally irrigated RF PVI con-
sisted of a large circumferential encircling of both ipsilateral
pulmonary veins (PVs). The technique is described in detail
elsewhere (7). In short, vascular access was obtained through
the right femoral vein, and a quadripolar catheter (Xtreme,
Sorin SPA, Milan, Italy) was positioned in the coronary
sinus. Double transseptal access was obtained and a
3-dimensional geometry of the LA was reconstructed with
a 3-dimensional electroanatomic mapping system (EnSite
Velocity, St. Jude Medical, St. Paul, Minnesota, or Carto 3,
Biosense Webster, Diamond Bar, California). The PV ostia
were carefully localized by combining the electrical signal
information with selective PV angiography. RF energy was
applied using an externally irrigated-tip catheter (Cool Path
Abbreviations
and Acronyms
ACT  activated clotting
time
AF  atrial fibrillation
INR  international
normalized ratio
LA  left atrium
MRI  magnetic resonance
imaging
PV  pulmonary vein
PVAC  multielectrode
duty-cycled radiofrequency
pulmonary vein ablation
catheter
PVI  pulmonary vein
isolation
RF  radiofrequency
TEE  transesophageal
echocardiographyDuo, St. Jude Medical or Thermo-Cool, Biosense-Webster) with a power between 25 and 35 W and an
irrigation rate of 17 to 40 ml/min according to the manu-
facturer’s recommendations to target a temperature of
45°C. Circumferential ablation was performed on the
posterior wall more than 1 cm and on the anterior wall more
than 5 mm away from the pre-defined PV ostia. When
residual PV conduction was present after circumferential
ablation around ipsilateral veins, PVs were mapped sequen-
tially using a circular mapping catheter (Optima, St. Jude
Medical or Lasso 2515 Variable, Biosense-Webster) to
localize the earliest PV potential. Further RF ablations were
placed on the circumferential line against the site with
earliest PV potential recorded on the circular mapping
catheter. To place the catheter as close as possible to the
ablation line, the diameter of the circumferential mapping
catheter was adjusted to the diameter of the PV antrum.
CRYOBALLOON PVI. The ablation procedure was performed
with the patients under general anesthesia and continuous
transesophageal echocardiographic monitoring. The tech-
nique for proper echocardiographic visualization of the PVs
and their flow was previously described (8). One single
transseptal puncture was made under transesophageal echo-
cardiographic guidance and a steerable sheath (Flexcath,
Cryocath Medtronic) was placed in the left atrium (LA).
Ablation was performed using a double-coated over-the-
wire cryoballoon (Arctic Front, Medtronic). The inner
lumen of the cryoballoon was connected to a continuous
pressure monitoring system. Balloon size was selected in
accordance with the diameter of the PVs, as measured by
transesophageal echocardiography (TEE). If all PVs had
a diameter 20 mm, the procedure was performed using a
23-mm cryoballoon; if any PV was 20 mm, we used a
28-mm balloon. The deflated cryoballoon was advanced
over an extra-rigid 0.032-mm guidewire placed inside each
PV (GuideRight Superstiff, St. Jude Medical or Amplatz
Extra-Stiff, Cook Medical, Bloomington, Indiana), and
inflated in front of the venous ostium. After inflation, the
balloon was advanced to achieve occlusion of the PV, as
assessed by TEE (9) and/or by the pressure curve (10). Each
PV was frozen twice over 5 min in the best occlusive
position. During ablation of the right PVs, we performed
continuous phrenic nerve pacing from the superior vena
cava to promptly detect phrenic nerve injury. If PV dimen-
sions were too heterogeneous, the size of the balloon was
switched to ensure proper occlusion. In case of persistent
conduction after cryoballoon ablation, electrical isolation
was segmentally completed using an 8-mm cryoablation
catheter (Freezor Max, Medtronic).
PHASED RF PVI USING PVAC. After gaining access through a
single transseptal puncture, a 10-F sheath (Frontier Ad-
vance, Ablation Frontiers Medtronic or Bard Channel, Bard
Electrophysiology Division, Lowell, Massachusetts) was
placed in the LA. Hand-held left atrial contrast injection
during high-rate ventricular pacing was performed for
simultaneous unselected PV angiograms. The PVAC is a
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and ablation catheter used in conjunction with the multi-
channel RF generator (GENius, Medtronic). The system is
capable of synchronous application of duty-cycled phased
unipolar and bipolar RF energy over all 10 PVAC elec-
trodes, where bipolar refers to adjacent electrodes. The
PVAC was directed over a guidewire placed in each of the
PVs toward the PV antrum, and 5 bipolar electrograms of
PV potentials were recorded over adjacent electrodes. En-
ergy delivery was applied in either a 4:1 or 2:1 bipolar-to-
unipolar ratio. Energy was limited to a maximum of 10 W
with an operator-defined temperature target of 60°C (tem-
perature controlled, power limited). Several overlapping RF
applications, 60 s each, were made while repositioning the
PVAC, until all PV potentials were eliminated (11). The
predefined diameter of the PVAC (25 mm) is designed to
deliver RF applications in the antral part of the PVs. The
PVAC was also used for validation of PV bidirectional
block.
ABLATION ENDPOINT. After ablation in each group, PVs
ere mapped using a circular mapping or the PVAC. The
ommon endpoint of all ablation procedures was complete
lectrical PV isolation, documented at least 30 min after the
ast application. No further left atrial ablation was permitted
n any group.
nticoagulation management. All patients received oral
nticoagulation 4 weeks before the procedure with a target
nternational normalized ratio (INR) of 2.0 to 3.0. Antico-
gulation was reduced or stopped 2 to 3 days before
blation, and patients presenting an INR 2.0 received
ubcutaneous low molecular weight heparin as a bridge to
he procedure. The INR was checked at least 1 day before
he procedure in all patients. On the day before ablation,
hey underwent TEE to rule out thrombi. An adjusted dose
f intravenous heparin was administered immediately after
he first transseptal access to target an activated clotting
ime (ACT) 300 s before starting ablation to obtain
omogeneous levels of anticoagulation during ablation in all
ur patients (12,13). Transseptal sheaths were continuously
erfused with heparinized saline solution to avoid clot
ormation or air embolism. No protamine was administered
t the end of the procedure. Immediately after the removal
f the catheters, oral anticoagulation was resumed, and all
atients received intravenous or low molecular weight hep-
rin until the INR was 2.5.
eurological examination and imaging. A systematic
linical neurological examination (including cranial nerve,
otor and sensory function, and gait assessment) was
erformed at admission, the day after the procedure, and 4
o 5 days after the procedure before discharge by the ward
hysician. Furthermore, all patients were monitored in the
ntensive care unit overnight after the procedure, including
valuation of consciousness and basic cranial nerve, motor,
nd sensory function every 15 min during the first 6 h.Cerebral MRI was performed 1 day before and 1 or 2
ays after ablation, using a 1.5-T unit (Siemens, Erlangen,
ermany). The pre-ablation imaging protocol consisted of
T2-weighted axial fluid-attenuated inversion recovery
equence (TI  2,500 ms, TR  9,000 ms, TE  116 ms,
6.0-mm slice thickness, 400  512 matrix) and a diffusion-
eighted echo planar imaging sequence (TR  3,500 ms,
E  87.0 ms, TA  00.13 ms, 6.0-mm slice thickness,
56  256 matrix). For each diffusion-weighted imaging
sequence, the apparent diffusion coefficient map was ob-
tained. After ablation, a T1-weighted spin echo sequence
and T2-weighted imaging were also performed. All se-
quences were centered on the axis defined by a line passing
between the anterior and posterior cerebral commissures.
On the post-ablation MRI, an acute embolic lesion was
defined as a focal hyperintense area detected by the fluid-
attenuated inversion recovery sequence, corresponding to a
restricted diffusion signal in the diffusion-weighted imaging
sequence, confirmed by apparent diffusion coefficient map-
ping to rule out a shine-through artifact. The number,
localization, and size of the focal lesions were analyzed.
Two certified radiologists blinded to the ablation tech-
nique independently analyzed all MRI scans. In case of
disagreement, the case was reviewed by a third radiologist.
Statistical analysis. The study was designed to include 240
patients (80 in each ablation group), based on a statistical
power of 0.8 to detect an incidence of embolic events 25%
higher in any group compared with the others, assuming an
 error of 0.05. Because it was a safety study, 2 interim
analyses were planned after the inclusion of 75 and 150
patients. The study was terminated in agreement with the
ethics committee after the first interim analysis because the
incidence of embolic events in the PVAC group was already
significantly higher.
Continuous variables are expressed as the mean  SD
and are compared using 1-way analysis of variance. A post
hoc analysis using Bonferroni correction was performed if
significant differences could be detected. For analysis involv-
ing only the 2 RF groups, we used the Student t test.
Categorical variables were compared using the chi-square
test. In that case, the p value threshold for statistical
significance was adjusted for multiple comparisons (0.05/3 
0.017). The odds ratio was calculated using binary logistic
regression, including parameters showing significant levels
of correlation with the presence of new embolic lesions on
univariate analysis. Statistical significance was set at p 
0.05.
Results
Patient characteristics. Baseline characteristics of the 74
patients included in the study are detailed in Table 1. There
were slightly more patients with persistent AF in the
externally irrigated RF group, whereas LA size was similar
among the groups. The thromboembolic risk profile was
well balanced among the groups (CHA2DS2VASc score:
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the cryoballoon group, and 1.3  1.0 in the PVAC group;
p  0.29).
Ablation procedure. Seventeen of the 74 patients pre-
sented in AF, and AF occurred during the procedure in
another 10 patients. Twenty-three patients underwent car-
dioversion during the procedure. The need for cardioversion
was similar in all 3 groups (30% in the externally irrigated
RF group, 22% in the cryoballoon group, and 42% in the
PVAC group; p  0.33).
All PVs could be successfully isolated after 41  14 min
of RF in the externally irrigated RF group and 25  9 min
of RF in the PVAC group (p  0.001). Despite the
significantly shorter ablation time, the total delivered energy
was similar in both RF groups (68,240  23,084 J for the
externally irrigated RF group and 80,540  43,447 J for the
PVAC group; p  0.28). Energy was delivered in a 4:1
mode in 54% of patients and in a 2:1 mode in the rest. In
the cryoballoon group, 5 of 23 patients (22%) were ablated
with the 23-mm balloon, 16 of 23 (70%) with the 28-mm
balloon, and 2 of 23 (9%) with both. In 14 of the 92 targeted
PVs (15%), supplementary focal cryoablation was necessary
to complete PVI.
Total procedure durations were 198  50 min in the
externally irrigated RF group, 174  35 min in the
cryoballoon group, and 124  32 min in the PVAC group
(p  0.001 for PVAC versus externally irrigated RF and
cryoballoon after Bonferroni correction). Total fluoroscopy
Patient CharacteristicsTable 1 Patient Characteristics
Externally Irrigated RF Grou
(n  27)
Age, yrs 61 10
Male 20 (74)
Hypertension 16 (59)
Structural heart disease 6 (22): CHD, 3;
myocarditis, 1;
tachymyopathy, 2
Persistent AF 14 (52)
LA, mm 42 5
Chronic lesions on MRI before ablation 6 (22)
CHA2DS2VASc score 1.7 1.5
Values are mean  SD or n (%).
CHD  coronary heart disease, DCMP  dilated cardiomyopathy; LA  left atrium; MRI  ma
catheter; RF  radiofrequency.
Procedure CharacteristicsTable 2 Procedure Characteristics
Externally Irrigated RF Group
(n  27)
Procedure time, min 198 50
Fluoroscopy time, min 34 17
Ablation time, min 41 14
Total energy delivered, J 68,240 23,084
Atrial fibrillation during the procedure 10 (37)
Need for cardioversion 8 (30)Values are mean  SD or n (%).
Abbreviations as in Table 1.times were 34  17 min in the externally irrigated RF
group, 27  13 min in the cryoballoon group, and 24  10
in in the PVAC group (p  0.051 for PVAC versus
xternally irrigated RF after Bonferroni correction). Proce-
ure characteristics for all 3 groups are summarized in Table 2.
Transient phrenic nerve paralysis occurred in 2 patients in
he cryoballoon group and resolved completely before dis-
harge. One cryoballoon procedure had to be aborted
ecause of pericardial effusion just after transseptal access
hrough an aneurysmal interatrial septum. The procedure
as rescheduled 1 month later and was successfully per-
ormed through a puncture done with an NRG RF trans-
eptal needle (Baylis, Toronto, Ontario, Canada). Finally, 1
atient in the externally irrigated RF group presented with
groin hematoma requiring surgical revision, and another
resented with generalized edema that resolved with di-
retic therapy.
ncidence of new embolic events after ablation. No overt
eurological events were observed, and findings on clinical
eurological examination were normal in all patients before
nd after ablation. Post-procedure MRI of 2 of 27 patients
7.4%) in the externally irrigated RF group and 1 of 23
4.3%) in the cryoballoon group revealed a new embolic
esion (Fig. 1). In the PVAC group, 9 of 24 patients (37.5%)
resented a median of 3 acute lesions (range, 1 to 5 acute
esions) on post-procedure MRI (Fig. 2). The presence of 1
r more new embolic lesions differed significantly among
he 3 groups (p  0.003), with the highest rate in the
Cryoballoon Group
(n  23)
PVAC
(n  24) p Value
61 7 59 10 0.62
15 (65) 15 (63) 0.65
14 (61) 11 (43) 0.51
3 (13): CHD, 1;
valvular, 1;
DCMP, 1
6 (25): CHD, 5;
DCMP, 1
0.57
8 (35) 6 (25) 0.13
40 6 41 5 0.47
2 (9) 1 (4) 0.16
1.7 1.3 1.3 1.0 0.52
resonance imaging; PVAC  multielectrode duty-cycled radiofrequency pulmonary vein ablation
Cryoballoon Group
(n  23)
PVAC
(n  24) p Value
174 35 124 32 0.001
27 13 24 10 0.035
45 7 25 9 0.001
— 80,540 43,447 0.28
7 (30) 10 (42) 0.43
5 (22) 10 (42) 0.33p
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similar in the 2 energy delivery modes (6 of 13 in 4:1 and 3
of 11 in 2:1, p  0.42). In 2 patients, macroscopic charring
formation could be observed on the PVAC electrodes at the
end of the procedure: 1 of them showed 2 new lesions on
post-intervention MRI and the other patient none. The
new lesions were broadly distributed over both hemispheres
(15 right-sided and 12 left-sided lesions), both supratento-
rial and infratentorial, but were located preferably in the
vertebrobasilar territory (16 of 27, 59%), supporting its
cardiac origin. The median lesion size was 5.5 mm (inter-
quartile range: 3.7 to 6.8 mm). Table 3 provides a summary
of these data. Intraprocedure anticoagulation was compara-
ble in those with or without new embolic lesions. Mean
intraprocedure ACT was 316  33 s in patients with versus
Figure 1 Cerebral Magnetic Resonance Imaging
Before and After Externally Irrigated RF PVI
Cerebral magnetic resonance imaging (diffusion-weighted echo planar imaging
sequence) showing the same cut before (A) and after (B) externally irrigated radiofre-
quency (RF) pulmonary vein isolation (PVI). The post-procedure magnetic resonance
imaging revealed a new right frontal embolic event (B, circled area).322  54 s in patients without emboli (p  0.649). TheFigure 2
Cerebral Magnetic Resonance Imaging
(Diffusion-Weighted Echo Planar
Imaging Sequence) After a PVAC PVI
The post-procedure examination showed multiple new embolic lesions (circled
areas). (A) Left cerebellar, (B) right cerebellar, and (C) bilateral temporo-occip-
ital lesions. PVAC  multielectrode duty-cycled radiofrequency pulmonary vein
ablation catheter; PVI  pulmonary vein isolation.
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Asymptomatic Embolisms and PV Ablation Techniques August 9, 2011:681–8need for cardioversion was also similar: 18% (2 of 11) in
patients with versus 33% (21 of 63) in patients without
embolic events (p  0.49). Univariate analysis searching for
redictors of new embolic events included catheter type,
ge, sex, hypertension, diabetes, structural heart disease, LA
ize, type of AF, rhythm, cardioversion, and mean ACT
uring ablation. The use of a PVAC remained the only
ignificant predictor of new ischemic events (odds ratio: 9.4,
5% confidence interval: 2.2 to 39.3; p  0.002).
iscussion
ecent studies have raised safety concerns about subclinical
mbolic events during PVIs (6,14). The current study aimed
o assess whether the ablation technique (conventional
pen-irrigated RF, multielectrode phased RF, or cryobal-
oon ablation) has an impact on the incidence of new
mbolic events detected by cerebral MRI. All 3 groups
resented new subclinical embolic lesions after PVI. How-
ver, the incidence and number of new lesions were signif-
cantly higher in patients treated with a PVAC, with a
redilection for the vertebrobasilar territory, favoring a
ardiac origin.
hromboembolic events after left atrial catheter ablation
rocedures. Although the incidence of clinical thrombo-
mbolic events after AF catheter ablation is low (0.94%) (5),
ecent studies have shown a substantial incidence of sub-
linical microembolic events, ranging from 8% to 14% after
ryoenergy or externally irrigated RF procedures (6,14–16).
Embolic events related to a PVI have several potential
auses. They may occur as a result of dislodgment of a
reexisting left atrial thrombus by catheter manipulation.
EE was performed in all our patients before the procedure
o exclude this possibility. Fresh thrombus can also form on
he sheath, the catheter, and over the newly created myo-
ardial lesions. As a matter of fact, systematic use of
ntracardiac echocardiography during left atrial ablation
rocedures detected as many as 10% of fresh thrombi
ttached to a sheath or a mapping catheter (17,18). To
inimize thrombus formation, all patients received ade-
uate anticoagulation both during and after ablation. Air
nd tissue debris can also be responsible for embolism.
Characteristics of New Embolic Events in All 3Table 3 Characteristics of New Embolic Eve
Externally Irrigated
(n  27)
Patients with new embolic events 2 (7.4)
No. of embolic lesions/patient 1
Size of embolic lesions, mm 6
Localization of embolic lesions Frontal (right):
cerebellar (lef
Values are n (%), mean  SD, or median (25th to 75th percentile).
Abbreviations as in Table 1.uring the procedure, all sheaths (including the 15-French clexcath sheath, Cryocath Medtronic) were carefully
ushed and constantly perfused with heparinized saline
olution, making an air embolism unlikely. Finally, charring
carbonization) is a real source of concern, especially with
onirrigated catheters (19). Only 1 of our patients with a
ew embolic lesion presented gross charring on the catheter
lectrodes after the procedure. However, larger charring
ormations might have dislodged during catheter with-
rawal inside the sheath.
The incidence of new embolic lesions found in externally
rrigated RF and cryoballoon groups was among the lowest
eported, similar to the one reported by Neumann et al. (14)
n the MEDAFI (Microembolization During Ablation of
trial Fibrillation) trial (7.9%). Our study population was
lso similar to that of the MEDAFI trial, with almost
wo-thirds of cases being paroxysmal AF, and none being
ong-standing AF. The type of AF, however, was not
ssociated with embolic events in any of the previous trials.
nother possible explanation for the relatively low embolic
vent rate in our cohort is the ablation strategy. Indeed, 8 of
3 patients who presented with acute intracranial lesions
fter the procedure in the study by Gaita et al. (6) received
ide-area ablation including linear lesions and atrial defrag-
entation. Expanding the set of lesions created also in-
reases the surface of damaged myocardium and therefore
he substrate for thrombus formation.
linical significance of subclinical intracranial embolic
vents after AF catheter ablation. All intracranial embolic
vents observed in our study were asymptomatic. Therefore,
hey would have remained unrecognized in everyday clinical
ractice.
Even without previous catheter ablation, patients with
F have been reported to have an increased prevalence of
ilent cerebral infarctions on routine MRI monitoring
ompared with matched patients in sinus rhythm (20). AF
atients have also been reported to have a higher incidence
f dementia than those in sinus rhythm (21). A recent study
y Schwarz et al. (15) found a significant neuropsycholog-
cal decline in patients after AF catheter ablation. Although
ot statistically related to the incidence of embolic lesions in
his small study (with only 2 new silent lesions), these events
sn All 3 Groups
oup Cryoballoon Group
(n  23)
PVAC
(n  24)
1 (4.3) 9 (37.5)
1 2.7 1.3
4 6.0 (4.5–8.5)
Temporo-occipital (right): 1 Cerebellar: 10
parietal: 5
occipital: 4
frontal: 5
*(13 right, 11 left)Groupnts i
RF Gr
1,
t): 1ould be clinically meaningful from a neurological point of
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notable rate of microembolic events, such as cardiac surgery
(22–24) and carotid stenting (25), have been correlated with
post-intervention neuropsychological deficits, although the
embolic load could not always be correlated with the degree
of cognitive deficits.
Silent intracranial embolism and PVAC technology. Al-
though not randomized, our 3 study groups had a similar
clinical thromboembolic risk profile and received the same
degree of anticoagulation during the procedure. Therefore,
the difference observed in the rate of new embolic events
seems to be catheter specific.
Duty cycling and phasing during energy delivery are
supposed to allow periodic cooling of the tissue and prevent
heating-related generation of thrombus or charring. How-
ever, this is highly dependent on tissue contact and local
blood flow, which are parameters that are extremely difficult
to assess on individual electrodes. This might lead to
overheating of some poles in some catheter positions and
therefore to carbonization. Software modifications of the
generator may help decrease temperature overshoots during
intermittent contact. Another possible burdensome point is
the lack of irrigation, especially considering that the PVAC
delivered the same amount of energy as an externally
irrigated RF catheter in almost half of the time. Irrigated-
tip catheters are routinely used in left atrial catheter abla-
tions because of a lower rate of thrombus formation or
carbonization compared with nonirrigated 4-mm catheters
(19). An intensified anticoagulation regimen or additional
platelet inhibition may reduce the embolic rate when using
PVAC technology, but may also increase the risk of bleed-
ing (especially secondary intracerebral hemorrhage). The
use of dabigatran instead of vitamin K inhibitors might also
have had an impact on the rate of embolic events. Further
studies might help to clarify this issue. Finally, routine use
of intracardiac echocardiography might have enabled iden-
tification and prevention of at least some of these embolic
events.
Study limitations. Patients were not randomized to the
ifferent techniques. Nevertheless, there were no differences
n the clinical characteristics of the patients. Each ablation
echnique was intentionally performed only by operators at
igh-volume centers, ensuring significant experience with
he technique.
Neither an exhaustive neurological examination nor stan-
ardized neuropsychological testing was performed in our
atients. Post-procedure minor neurological deficits or neu-
ocognitive alterations may have been missed in this study.
Used in everyday clinical management of intraprocedure
nticoagulation, the ACT remains a very dynamic parame-
er. A mean ACT 300 s cannot be taken as a guarantee of
consistent anticoagulation throughout the procedure. Sys-
ematic ACT testing every 20 min could have improved
nticoagulation levels and prevented some embolic events.Finally, the sample size and event count were very small.
This did not allow us to search for additional predictors of
new embolic events with multivariate analysis.
Conclusions
PVI performed with the PVAC presents a notably higher
incidence of subclinical intracranial embolic events than if
performed with an externally irrigated RF catheter or a
cryoballoon. Improvement in PVAC technology and further
studies to clarify the origin of these embolic lesions are
mandatory to reduce the rate of silent embolisms during
ablation procedures in the LA.
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